Inventor · disambiguated record
Joanna Opalinska
Also filed as: OPALINSKA JOANNA
3 granted patents·8 pending applications·0 citations·filing 2018–2025
50Inventor score
Files withGLAXOSMITHKLINE IP DEV LTD11
Top patents by PatentIndex Score
11 records- 0176US12227585B2Anti-BCMA antibody drug conjugate combination treatment for cancerGLAXOSMITHKLINE IP DEV LTD·Filed 2023·Granted Feb 18, 2025·0 cites·20 claims
- 0275US2025122297A1Anti-BCMA Antibody Drug Conjugate Combination Treatment for CancerGLAXOSMITHKLINE IP DEV LTD·Filed 2024·Application pending·0 cites
- 0372US12234293B2Treatment for primary amyloidosis with anti-BCMA binding proteinGLAXOSMITHKLINE IP DEV LTD·Filed 2022·Granted Feb 25, 2025·0 cites·19 claims
- 0461US2025163172A1Combination Treatment for CancerGLAXOSMITHKLINE IP DEV LTD·Filed 2025·Application pending·0 cites
- 0559US11401334B2Combination treatment for cancer with anti-BCMA binding protein and proteosome inhibitorGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Granted Aug 2, 2022·0 cites·5 claims
- 0658US2022411512A1Combination treatment for cancerGLAXOSMITHKLINE IP DEV LTD·Filed 2022·Application pending·0 cites
- 0751US2020255526A1Combination treatment for cancerGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
- 0849US2020254093A1Combination treatment for cancerGLAXOSMITHKLINE IP DEV LTD·Filed 2018·Application pending·0 cites
- 0941US2022096650A1Belantamab mafodotin in combination with pembrolizumab for treating cancerGLAXOSMITHKLINE IP DEV LTD·Filed 2020·Application pending·0 cites
- 1039US2022098303A1Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereofGLAXOSMITHKLINE IP DEV LTD·Filed 2020·Application pending·0 cites
- 1139US2022003772A1Methods of treating cancerGLAXOSMITHKLINE IP DEV LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Joanna Opalinska files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →